LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Longeveron Inc. (LGVN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B (3.3) | C (2.2) | B- (2.9) | F (0.6) | C+ (2.6) | C (2.3) |
| 2026-11-06 | B (3.4) | C (2.2) | B- (2.9) | F (0.5) | C+ (2.7) | C (2.3) |
| 2026-10-30 | B (3.3) | B (3.3) | B (3.3) | F (0.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-23 | B (3.3) | B (3.3) | B (3.3) | F (0.5) | C+ (2.6) | C+ (2.6) |
| 2026-10-16 | B (3.4) | B (3.3) | B (3.3) | D- (1.1) | C+ (2.6) | C+ (2.7) |